These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9789202)

  • 1. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.
    Franchini L; Serretti A; Gasperini M; Smeraldi E
    J Psychiatr Res; 1998; 32(5):255-9. PubMed ID: 9789202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
    Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
    Okumura T; Kishi T; Okochi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Tsunoka T; Inada T; Ozaki N; Iwata N
    Neuropsychobiology; 2010; 61(2):57-63. PubMed ID: 20016223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes.
    Papolos D; Mattis S; Golshan S; Molay F
    J Affect Disord; 2009 Nov; 118(1-3):28-38. PubMed ID: 19631388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sexual desire during fluvoxamine treatment.
    Okada F; Okajima K
    Can J Psychiatry; 2000 Oct; 45(8):762-3. PubMed ID: 11086562
    [No Abstract]   [Full Text] [Related]  

  • 13. Sex differences in the familial transmission of mood disorders.
    Currier D; Mann MJ; Oquendo MA; Galfalvy H; Mann JJ
    J Affect Disord; 2006 Oct; 95(1-3):51-60. PubMed ID: 16793141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family study of fibromyalgia.
    Arnold LM; Hudson JI; Hess EV; Ware AE; Fritz DA; Auchenbach MB; Starck LO; Keck PE
    Arthritis Rheum; 2004 Mar; 50(3):944-52. PubMed ID: 15022338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
    Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns of symptom improvement during antidepressant treatment of delusional depression.
    Serretti A; Lattuada E; Zanardi R; Franchini L; Smeraldi E
    Psychiatry Res; 2000 May; 94(2):185-90. PubMed ID: 10808044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
    Ueda N; Terao T; Ohmori O; Nakamura J
    Hum Psychopharmacol; 2003 Aug; 18(6):477-8. PubMed ID: 12923827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.